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Abstract
Background:	Despite	remarkable	advances	in	our	understanding	of	asthma,	there	are	
still	several	unmet	needs	associated	with	the	management	of	pediatric	asthma.
Methods:	A	two‐day,	face‐to‐face	meeting	was	held	in	London,	United	Kingdom,	on	
October	 28	 and	 29,	 2017,	 involving	 a	 group	 of	 international	 expert	 clinicians	 and	
scientists	 in	 asthma	management	 to	discuss	 the	 challenges	 and	unmet	needs	 that	
remain	to	be	addressed	in	pediatric	asthma.
Results:	These	unmet	needs	 include	a	 lack	of	clinical	efficacy	and	safety	evidence,	
and	limited	availability	of	non‐steroid‐based	alternative	therapies	in	patients	<6	years	
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1  | INTRODUC TION
Asthma	is	a	chronic	airway	condition	affecting	approximately	10%	of	
children	in	the	European	Union	(EU)1	and	North	America,2,3	with	an	
even	higher	prevalence	observed	in	some	other	areas,	such	as	South	
America.4	Asthma	comprises	a	serious	personal,	familial,	and	global	
economic	burden,	including	school	and	employment	absences,	hos‐
pital	care,	and	drug	expenditures.5,6	To	an	even	greater	extent	than	
has	 been	 observed	 for	 adult	 patients	 with	 asthma,	 considerable	
variation	in	pediatric	asthma	severity,	natural	disease	history,	clini‐
cal	phenotype,	and	response	to	therapy	can	exist	between	patients,	
establishing	asthma	as	a	condition	with	significant	heterogeneity.7
Despite	 remarkable	 advances	 in	 our	 understanding	 of	 this	
condition,	 and	 the	 availability	 and	 current	 development	 of	 novel	
medications	 for	 the	 treatment	 of	 asthma,	 many	 asthma	 patients	
remain	 uncontrolled,	which	 imposes	 a	 significant	 ongoing	 burden.	
Uncontrolled	pediatric	asthma	is	associated	with	increased	exacer‐
bation	rate,	impaired	quality	of	life,	and	persisting	bronchial	obstruc‐
tion.8,9	Current	clinical	practice	guidelines	do	not	always	adequately	
address	 pediatric	 asthma,	 a	 feature	 that	 is	 probably	 linked	 to	 the	
limited	availability	of	clinical	efficacy	and	safety	data	in	younger	pa‐
tients,	often	resulting	in	an	extrapolation	of	adult	recommendations	
to	children.	This	dearth	of	evidence	may	impact	on	local	reimburse‐
ment	or	resourcing	policies	and	therefore	on	the	accessibility	of	po‐
tentially	effective	medicines	for	this	patient	population.10
There	is	an	urgent	need	for	an	up‐to‐date	assessment	of	the	true	
burden	and	unmet	needs	of	asthma	patients,	and	their	families,	to	en‐
sure	 appropriate	 support	 to	meet	 these	needs.	 Provisions	 to	 ensure	
better	asthma	control	at	an	earlier	stage	may	facilitate	improved	quality	
of	 life	and	significant	 long‐term	cost	savings	 for	both	asthma	suffer‐
ers	and	society.11	This	article	is	a	scoping	review	of	the	current	unmet	
needs	of	children	with	asthma	(Table	1)	and	the	potential	role	for	effec‐
tive	therapies	in	this	vulnerable	patient	population.	Content	has	been	
developed	from	review	of	the	literature	and	synthesized	with	expert	
opinion	during	a	face‐to‐face,	two‐day	meeting	with	a	group	of	interna‐
tional	expert	clinicians	and	scientists	in	pediatric	asthma	management.
2  | UNMET NEEDS IN PEDIATRIC A STHMA
2.1 | Guidelines that acknowledge the management 
of different asthma phenotypes
Diagnosing	asthma	and	establishing	control	as	early	as	possible	 in	
childhood	 are	 considerable	 clinical	 challenges.	 Clinical	 practice	
guidelines	are	in	place	to	support	healthcare	practitioners	(HCPs)	in	
the	management	of	pediatric	asthma12,13;	however,	these	may	not	be	
totally	suitable	to	ensure	optimal	management	of	asthma	in	the	real‐
life,	day‐to‐day	clinical	setting.	This	is	largely	due	to	a	lack	of	relevant	
evidence	and	different	patterns	of	asthma	in	children.13
of	age.	An	 increased	 focus	on	children	 is	needed	 in	 the	context	of	clinical	practice	
guidelines	for	asthma;	current	pediatric	practice	relies	mostly	on	extrapolations	from	
adult	recommendations.	Furthermore,	no	uniform	definition	of	pediatric	asthma	ex‐
ists,	which	hampers	timely	and	robust	diagnosis	of	the	condition	in	affected	patients.
Conclusions:	There	is	a	need	for	a	uniform	definition	of	pediatric	asthma,	clearly	distin‐
guishable	from	adult	asthma.	Furthermore,	guidelines	which	provide	specific	treatment	
recommendations	 for	 the	management	of	pediatric	 asthma	are	also	needed.	Clinical	
trials	and	real‐world	evidence	studies	assessing	anti‐immunoglobulin	E	(IgE)	therapies	
and	other	monoclonal	antibodies	in	children	<6	years	of	age	with	asthma	may	provide	
further	information	regarding	the	most	appropriate	treatment	options	in	these	vulner‐
able	patients.	Early	intervention	with	anti‐IgE	and	non‐steroid‐based	alternative	thera‐
pies	may	delay	disease	progression,	leading	to	improved	clinical	outcomes.
K E Y W O R D S
asthma	management,	omalizumab,	pediatric	asthma,	unmet	need
TA B L E  1  Unmet	needs	in	pediatric	patients	with	asthma
Lack	of	clinical	efficacy	and	safety	evidence	of	biologics	in	patients	
<6	years
Limited	availability	of	non‐steroid‐based	alternative	therapies
Lack	of	available	therapies	for	children	with	severe	asthma
Difficult	diagnosis	in	children
Scarcity	of	studies	on	allergen	immunotherapy	in	children
Limited	access	to	specialist	pediatric	asthma	care	in	some	countries
No	uniform	definition	of	pediatric	asthma	or	pediatric	asthma	
control
Inadequate	pediatric	focus	in	current	clinical	practice	guidelines
Lack	of	data	on	asthma	endotypes/phenotypes
Lack	of	well‐defined	pediatric	treatable	traits
Lack	of	molecular	studies
Lack	of	data	on	personalized	treatment	strategies	based	on	a	
phenotype	(endotype)	approach
Lack	of	treatment	options	for	comorbidities
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Asthma	is	not	a	simple,	single	disease	entity;	the	existence	of	a	
variety	of	clinical	presentations	(phenotypes)	and	underlying	mech‐
anisms	 (endotypes),	 coupled	with	 the	 presence	 of	 symptoms	 that	
overlap	with	other	acute	and	chronic	conditions,	make	the	diagnosis	
of	asthma	challenging	for	HCPs.14	Although	the	role	of	allergy	in	pe‐
diatric	asthma	has	been	highlighted,15,16	our	current	understanding	
of	the	role	of	phenotypes	and	endotypes	is	limited	in	children	and	is	
complicated	by	the	fact	that	the	immune	system	in	children	is	con‐
stantly	 developing	 and	maturing.	 Therefore,	 it	 is	 likely	 that	 differ‐
ences	exist	in	pathophysiology	and	inflammatory	signaling	in	asthma	
in	children	compared	with	adults,	and	even	compared	with	children	
of	different	ages.17,18	It	is	for	this	reason	that	molecular	studies	are	
required	to	provide	a	much	deeper	understanding	of	the	 immuno‐
logic	mechanisms	underlying	allergy	and	asthma	in	association	with	
developmental	 milestones	 (and	 indeed	 underlying	 each	 distinct	
phenotype).19	 Such	 knowledge	 may	 facilitate	 the	 development	 of	
mechanism‐	or	phenotype‐driven	 treatment	options	 in	 children	 to	
establish	control	in	the	early	stages	of	asthma.
The	Global	Initiative	for	Asthma	(GINA)	definition	of	asthma	was	
recently	updated;	asthma	is	proposed	to	be	“a heterogeneous disease, 
usually characterized by chronic airway inflammation. It is defined by 
the history of respiratory symptoms such as wheeze, shortness of breath, 
chest tightness and cough that vary over time and in intensity, together 
with variable expiratory airflow limitation”.12
The	direct	application	of	this	definition	to	pediatric	patients	re‐
mains	restricted,	especially	in	patients	<6	years	of	age.	Wheeze,	al‐
though	a	hallmark	of	pediatric	asthma,	can	be	a	symptom	of	other	
conditions	 too	 and	 can	 be	misdiagnosed	 as	 asthma	 in	 young	 chil‐
dren,	 leading	 to	 the	 inappropriate	 prescription	 of	 inhaled	 cortico‐
steroids	 (ICS).	 Furthermore,	 the	 relationship	 between	 pre‐school	
wheeze	and	asthma	remains	debatable.20	In	children,	an	increase	in	
post‐bronchodilator	 reversibility	as	measured	by	 forced	expiratory	
volume	 in	 one	 second	 (FEV1)	 of	 >12%	 predicted	 is	 recommended	
to	 fulfill	 the	 variable	 expiratory	 airflow	 limitation	 criterion	 of	 the	
definition	 of	 asthma.12	 Outside	 of	 an	 acute	 exacerbation	 setting,	
12%	improvement	can	be	difficult	to	demonstrate	 in	children	with	
asthma,	in	whom	FEV1	levels	are	most	often	in	the	normal	range.
21 
Furthermore,	airflow	 limitation	assessment	with	spirometry	or	 im‐
pulse	oscillometry	 can	be	 challenging	 in	 young	children,	making	 it	
difficult	to	conclusively	meet	the	definition	of	asthma.22,23	In	these	
cases,	 asthma	diagnosis	 is	 essentially	based	on	 clinical	 criteria.	Of	
note,	 the	National	 Institute	 for	Health	and	Care	Excellence	 (NICE)	
guidelines	recommend	fractional	exhaled	nitric	oxide	(FeNO)	testing	
in	children	(5–16	years)	in	cases	of	diagnostic	ambiguity.24
The	inability	to	reach	a	robust	and	universal	definition	of	asthma	
is	 not	 a	 new	 phenomenon	 and	 is	 evidenced	 by	 the	 differing	 ap‐
proaches	 currently	 in	 existence.	 These	 discrepancies	 have	 been	
extensively	 discussed	 by	 the	 International	 Consensus	 on	 (ICON)	
Pediatric	Asthma	group,	where	they	also	highlighted	a	lack	of	distinc‐
tion	in	any	current	asthma	guideline	between	the	definitions	of	adult	
versus	pediatric	asthma.13	Of	note,	the	Lancet	Asthma	Commission	
has	recently	put	forward	a	new	proposal	to	use	“asthma”	to	describe	
a	collection	of	overlapping	symptoms,	rather	than	as	a	single	disease	
entity	or	an	indicator	for	a	specific	pathophysiology.25	Interestingly,	
this	approach	is	similar	to	the	original	use	of	the	word	“asthma”	by	
Homer	more	than	2500	years	ago.26
Furthermore,	 it	 is	 not	 clear	 to	what	 extent	 the	 severity	 gradi‐
ent	observed	among	asthma	patients	and	mentioned	in	guidelines,	
that	is,	mild,	moderate,	and	severe	asthma,	represents	a	continuous	
spectrum	or	 reflects	differences	 in	pathophysiology.	Such	 labeling	
systems	are	 likely	to	affect	future	treatment	strategies	as	children	
with	asthma	mature.	New	data	on	the	natural	history	of	asthma	may	
help	to	inform	such	therapeutic	implications	(Figure	1).
2.2 | Timely and appropriate referral from primary 
care providers
Systems	of	care	for	pediatric	asthma	patients	vary	between	coun‐
tries.	In	some	countries,	asthma	is	mainly	diagnosed	and	cared	for	by	
general	practitioners	and	primary	care	physicians	(GPs/PCPs),	while	
in	other	countries,	children	have	more	access	to	specialist	care.	This	
may	have	an	 important	 impact	upon	asthma	control	and	access	to	
advanced	therapies.	In	systems	where	the	GP/PCP	plays	a	dominant	
role,	referral	of	certain	asthma	patients	for	specialized	care	is	often	
necessary.	Table	2	describes	a	number	of	potential	roles	of	the	spe‐
cialized	care	center	 for	pediatric	asthma.	Although	patient	 referral	
recommendations	are	addressed	in	clinical	practice	guidelines,	fail‐
ure	to	promptly	refer	a	patient	from	primary	to	specialist	care	 is	a	
potential	barrier	to	the	effective	management	of	pediatric	asthma.14
In	countries	where	a	significant	portion	of	asthma	management	
is	delivered	in	busy	primary	care	clinics,	GPs/PCPs	are	in	an	import‐
ant	 position	 to	 identify	 uncontrolled	 or	 difficult‐to‐treat	 asthma.	
The	 importance	of	 local	 factors	 in	the	primary	care	setting	should	
not	 be	 overlooked;	 local	 environmental	 triggers	 of	 symptoms	 and	
the	 ability	 to	 adapt	 global	 strategy	 documents	 to	 suit	 local	 needs	
should	also	be	considered.27	An	extensive	overview	of	guideline	rec‐
ommendations	for	the	referral	of	adults	with	asthma	is	available.14 
Similar	guideline‐defined	recommendations	are	relatively	limited	for	
children,	although	the	Canadian	pediatric	guidelines	do	recommend	
referral	in	the	case	of	diagnostic	uncertainty	or	uncontrolled	asthma	
on	medium‐dose	 ICS.28	 It	 is	 critical	 that	 local	 healthcare	 systems	
have	clear	guidance	in	place	to	support	GPs/PCPs	in	the	referral	of	
such	patients	to	a	specialist	in	appropriate	instances,	but	this	is	not	
always	available.	This	guidance	is	important	as	it	is	not	feasible	to	ex‐
pect	a	GP/PCP	to	have	the	time	or	resources	to	optimize	treatment	
in	difficult	cases,	owing	to	the	very	broad	range	of	conditions	and	
patients	presenting	to	primary	care	facilities.29	The	use	of	electronic	
diaries	and	mobile	health	technology	may	significantly	improve	the	
management	of	pediatric	asthma,	and	the	communication	between	
the	GP/PCP	and	the	specialist.30,31
Increased	 awareness	 of	 effective	 referral	 strategies	 and	 im‐
proved	communication	between	GPs/PCPs	and	specialists	may	im‐
prove	 the	 rate	 of	 appropriate	 referrals.29	 The	 time	 to	 referral	will	
ultimately	depend	on	local	healthcare	regulations	and	resources	of	
GPs/PCPs.14	 Local	 implementation	 of	 strategies	 to	 support	 GPs/
PCPs	 in	 the	 delivery	 of	 pediatric	 asthma	 care	 and	 appropriate	
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referral	guidelines	may	improve	clinical	outcomes	for	children	with	
asthma.	Referral	of	pediatric	patients	with	severe	asthma	to	a	spe‐
cialist	 should	 be	 considered	 with	 high‐priority	 status,	 even	 if	 the	
condition	 is	 controlled.32	This	expert	panel	 suggests	 the	 following	
algorithm	for	when	referral	may	be	considered:	3–4	courses	of	oral	
corticosteroids	 in	a	year,	or	a	severe	exacerbation	requiring	hospi‐
talization,	or	atypical	symptoms	suggesting	an	alternative	diagnosis	
(unpublished).
2.3 | Effective treatment options
As	with	adults,	the	ultimate	goals	of	pediatric	asthma	management	in‐
clude	adequate	symptom	control	and	reduced	future	risks.12	Natural	
history	modification	and	possible	disease	prevention	are	also	of	high	
importance	in	children.33	Achieving	asthma	control	usually	requires	
pharmacological	 intervention,	 including	 controller	medication,	 res‐
cue	medication,	and	add‐on	therapy,	in	the	case	of	severe	asthma.12 
Equally	 as	 important	 are	 the	 non‐pharmacological	 treatment	 ap‐
proaches,	which	are	 frequently	underestimated.	These	 include	pa‐
tient	 education	 and	 trigger	 avoidance	 (eg,	 minimizing	 exposure	 to	
pollutants	and	allergens	to	reduce	asthma‐associated	morbidity).34,35
Corticosteroids	 play	 a	 central	 role	 in	 the	 pharmacological	
management	 of	 asthma.	Over	 the	 last	 six	 decades,	 the	 clinical	 ef‐
fectiveness	of	corticosteroid	treatment	in	asthma	has	been	demon‐
strated.36‐38	 The	mainstay	 controller	 medication	 used	 in	 pediatric	
asthma	to	limit	airway	inflammation	is	an	ICS,	as	it	has	been	shown	
to	significantly	improve	lung	function39	and	reduce	exacerbations.40 
However,	ICS	dose	regimens	that	are	suitable	for	the	pediatric	pop‐
ulation	vary	across	different	guidelines,	as	do	 the	 thresholds	used	
to	define	low‐,	medium‐,	and	high‐dose	ICS.	There	is	also	high	vari‐
ability	of	dose	delivered	according	to	device	choice.41	The	need	for	
guidelines	to	be	updated	according	to	ICS	dose	responses	has	also	
been	highlighted	previously.42
TA B L E  2  The	roles	of	the	specialized	care	center	for	pediatric	
patients	with	asthma
Diagnosis,	including	differential	diagnosis
Managing	severe	asthma
Phenotype/endotype	approaches
Personalized	treatments
Clinical	trials
Educational	programs
Treatment‐related	adverse	event	surveys
Transition	to	adulthood	and	adult	asthma	services
Implementation	of	cooperative	strategies	between	GPs/PCPs	and	
asthma	specialists
Biologic	and	other	therapies	reserved	for	severe	asthmatics
Cohort	studies
GPs,	general	practitioners;	PCPs,	primary	care	physicians
F I G U R E  1  Present	inadequacies	and	
potential	future	realities	of	pediatric	
asthma	management
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Furthermore,	 delivery	 via	 the	 inhaled	 route	 can	 be	 ineffective	
in	children	<5	years	 in	whom	drug	deposition	 to	 the	 lungs	may	be	
compromised	 by	 improper	 inhalation	 technique	 or	 anatomic	 fac‐
tors.43	Potential	side	effects	of	their	use	remain	an	important	issue	
in	relation	to	parents’	adherence	and	should	always	be	considered	
by	HCPs.44	Although	ICS	use	in	children	is	important	and	effective,	
there	 are	 non‐frequent,	 but	 potentially	 serious,	 adverse	 effects	
associated	 with	 their	 use.	 These	 include	 possible	 height	 deficits,	
increased	 susceptibility	 to	 infection,	 and	 hypothalamic‐pituitary‐
adrenal	(HPA)	axis	suppression,	potentially	leading	to	adrenal	crisis	
or	growth	retardation	 in	children.44‐47	As	the	 incidence	of	adverse	
events	 is	 often	 dose‐dependent,	 the	 minimum	 effective	 dose	 in	
order	to	achieve	uncompromised	asthma	control	should	always	be	
considered.44
As	 per	 clinical	 guideline	 recommendations,	 short	 courses	 of	
oral	 corticosteroids	 (OCS)	 are	 used	 to	 effectively	 treat	 exacer‐
bations.12	 However,	 frequent	 OCS	 use	 for	 exacerbations,	 espe‐
cially	at	higher	doses,	 is	associated	with	a	wide	range	of	adverse	
effects	 in	children	 including	growth	 impairment,48 reduced bone 
density,46	and	behavioral	effects.49	Also,	the	association	between	
OCS	 and	 bone	 fractures	 has	 been	 highlighted	 in	 a	 recent	multi‐
variate	analysis	which	demonstrated	a	17%	increased	risk	of	bone	
fracture	in	pediatric	patients	after	one	OCS	prescription	compared	
with	none.50	 It	 is	therefore	important	to	monitor	 level	of	control	
regularly	and	adjust	the	preventative	treatment	accordingly.	If	the	
severity	of	asthma	requires	increasing	the	regular	dose	of	ICS	(or	
combination	therapy),	or	OCS	bursts	beyond	an	acceptable	level,	
it	 is	 important	 to	 consider	 corticosteroid‐sparing	 strategies	 in	
this	particular	patient	population.	To	this	end,	long‐acting	β2‐ago‐
nists	(LABAs)	are	indeed	available	for	the	treatment	of	asthma	in	
school‐aged	children	and	older,	and	they	are	frequently	prescribed	
in	 combination	 with	 an	 ICS.	 Of	 note,	 the	 black	 box	 warning	 on	
medicines	 containing	 both	 an	 ICS	 and	 a	 LABA	was	 recently	 re‐
moved	by	the	US	Food	and	Drug	Administration,	presumably	af‐
fording	more	“peace	of	mind”	to	HCPs	and	caregivers	of	children	
receiving	 these	medications.	 Tiotropium	 is	 a	 long‐acting	musca‐
rinic	 antagonist	 (LAMA)	 recently	 approved	 for	 children	with	 se‐
vere	asthma	≥6	years	of	age,	providing	another	treatment	option	
for	GINA	step	4	and	5	patients.	Furthermore,	in	patients	≥6	years	
of	 age	with	 severe	 asthma,	 add‐on	 anti‐IgE	 therapy	with	 omali‐
zumab	 has	 shown	 clinical	 efficacy	 and	 also	 reduces	 OCS	 use.51 
Similar	efficacy	data	are	still	unavailable	for	patients	<6	years	due	
to	a	lack	of	appropriate	studies.
3  | POTENTIAL FOR BIOLOGIC S A S 
NON‐STEROID ‐BA SED TRE ATMENTS IN 
PEDIATRIC A STHMA
An	important	question	in	the	era	of	stratified	medicine	is	what	can	
be	 done	 beyond	 corticosteroids.	 Stratified	 or	 personalized	 medi‐
cine	recognizes	that	the	underlying	mechanisms	of	asthma	can	vary	
significantly	between	patients,	and	 it	 is	widely	acknowledged	 that	
there	is	a	need	for	non‐steroid‐based	treatment	approaches	in	the	
management	of	asthma,	especially	in	children.52
With	the	rapid	emergence	of	many	biologics	for	the	treatment	of	
adult	asthma	 (including	anti‐IgE,	anti‐interleukin	 [IL]‐5,	anti‐IL‐5Rα,	
anti‐IL‐13,	and	anti‐thymic	stromal	lymphopoietin	monoclonal	anti‐
body	approaches),53	there	is	increased	interest	in	their	potential	use	
in	pediatric	patients.	Establishing	disease	control	as	early	as	possi‐
ble	in	pediatric	asthma	is	critical,	as	is	the	prevention	of	asthma	or	
disease	 progression;	 however,	 asthma	management	 in	 very	 young	
patients	 is	 based	 largely	 on	 clinical	 judgment,	 expert	 opinion,	 and	
cost	of	medications	owing	to	the	lack	of	clinical	evidence	in	this	par‐
ticular	patient	population.54	As	described	previously	by	Szefler	and	
colleagues,	“the younger the child, the less information there is available 
to guide clinicians”.33	We	would	also	add	that	the	younger	the	child,	
the	later	he/she	can	benefit	from	medical	progress.
Omalizumab	is	currently	the	only	anti‐IgE	monoclonal	antibody	
with	 an	 approved	 indication	 in	 children	 ≥6	years	 (EU).	 In	 the	 EU,	
omalizumab	is	approved	as	add‐on	treatment	in	patients	≥6	years	of	
age	with	severe	persistent	allergic	asthma	that	is	not	sufficiently	con‐
trolled	with	ICS	plus	LABA	therapy55	and	in	the	United	States	(US)	for	
patients	≥6	years	with	moderate‐to‐severe	persistent	asthma	with	a	
positive	skin	test	or	in	vitro	reactivity	to	a	perennial	aeroallergen	and	
symptoms	 that	 are	 not	 sufficiently	 controlled	with	 ICS	monother‐
apy.56	 This	 labeling	 excludes	 asthma	 patients	 <6	years	who	might	
benefit	from	anti‐IgE	therapy	and	limits	the	add‐on	therapy	options	
available	 to	 physicians.	 Studies	 demonstrating	 the	 efficacy	 and	
safety	of	omalizumab	in	pre‐school	children	and	milder	patients	are	
currently	in	planning,	while	similar	studies	involving	other	biologics	
are	urgently	required.	Mepolizumab	is	an	anti‐IL‐5	monoclonal	anti‐
body	approved	for	the	treatment	of	patients	≥18	years	(≥12	years	in	
some	countries)	with	eosinophilic	asthma,	and	 it	 is	encouraging	 to	
note	that	other	anti‐IL‐5Rα	and	anti‐IL‐4Rα	 therapies	are	currently	
under	investigation	in	patients	≥12	years.53	Although	the	results	of	
studies	of	 these	biologics,	 including	mepolizumab57,58 and benrali‐
zumab,59,60	are	a	very	positive	step	forward	for	patients	with	asthma,	
it	 is	disappointing	 that	only	a	 limited	number	of	adolescents	were	
included	in	these	initial	trials.61	Furthermore,	the	efficacy	of	these	
promising	therapies	in	patients	below	this	age	threshold	(<12	years)	
is	entirely	unknown.	It	would	be	unfortunate	if	today’s	pediatric	pa‐
tients	 reach	adulthood	without	getting	 the	opportunity	 to	experi‐
ence	the	potential	benefits	that	any	of	these	biologic	therapies	may	
have	had	on	their	asthma	and	quality	of	 life.	For	this	reason,	more	
studies	of	longer	duration	that	include	children	of	all	age	groups	are	
urgently	needed	to	provide	additional	data	on	the	efficacy	of	these	
biologics.	However,	the	authors	acknowledge	that	the	relatively	low	
prevalence	of	severe	refractory	asthma	in	younger	children	may	im‐
pede	the	recruitment	of	these	patients	for	such	studies.
Furthermore,	safety	is	an	urgent,	outstanding	issue	when	treat‐
ing	children	with	asthma—there	is	a	serious	lack	of	safety	information	
regarding	biologics	(with	the	exception	of	omalizumab)	for	patients	
below	the	age	of	18	years.	While	over	10	years	of	omalizumab	use	
has	 suggested	a	 favorable	 long‐term	safety	profile	 in	 children	and	
adolescents,62	all	other	biologic	therapies	need	to	demonstrate	the	
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same	as	soon	as	possible.	Results	of	such	studies	may	allow	better	
informed	treatment	recommendations	to	be	disseminated	by	guide‐
line	committees	in	the	future.
An	unmet	need	 that	 is	particularly	 relevant	 for	young	children	
(particularly	 those	 <6	years)	 with	 asthma	 (where	 significant	 im‐
pact	could	be	made	on	the	course	of	disease	at	this	early	stage	of	
life)	 is	the	possibility	of	preventing	(or	delaying)	the	progression	of	
asthma	severity	using	effective	therapeutic	intervention	at	a	young	
age.63	 Although	we	 have	 observed	 some	 promising	 data	with	 im‐
munotherapy	 in	 children	 (5–12	years)	 to	 date,64	 studies	 assessing	
current	asthma	therapies	in	infants	have	been	sparse.	It	is	possible	
that	omalizumab	can	modify	disease	or	prevent	disease	progression,	
which	 are	 characteristics	 that	will	 be	 evaluated	 in	 the	 Preventing	
Asthma	in	high	Risk	Kids	(PARK)	study	in	the	United	States	(https://
clinicaltrials.gov/ct2/show/NCT02570984).	 In	 this	 study,	 which	 is	
due	to	commence	in	2018,	children	aged	2–3	years	with	a	history	of	
2–4	wheezing	episodes	in	the	previous	year	and	positive	aeroaller‐
gen	allergy	will	receive	omalizumab	or	placebo	for	2	years	and	will	be	
followed	for	an	additional	2	years.	The	co‐primary	outcomes	of	the	
PARK	study	are	(a)	active	asthma	diagnosis	and	(b)	asthma	severity	
assessed	by	the	validated	composite	asthma	severity	index	(CASI),65 
which	combines	symptoms,	medication	use,	and	lung	function	into	
the	score	 (time	frame:	final	12	months,	during	the	2‐year	observa‐
tion	period	off	the	study	drug).	If	this	study	demonstrates	a	signifi‐
cant	benefit	of	anti‐IgE	therapy	in	infants,	its	use	in	younger	asthma	
patients	will	be	worth	considering	in	the	future.
Ultimately,	owing	to	the	known	heterogeneity	that	exists	among	
children	with	asthma,	it	stands	to	reason	that	a	personalized	treat‐
ment	 rather	 than	 a	 universal	 “one‐size‐fits‐all”	 approach	 should	
be	 developed.	 The	 promising	 results	 of	 the	 recent	 Individualized	
Therapy	 for	 Persistent	Asthma	 in	Young	Children	 (INFANT)	 study	
support	this,	wherein	74%	of	children	showed	clinically	relevant	re‐
sponses	 to	 one	 treatment	 over	 others,	 and	 blood	 eosinophils	 and	
aeroallergen	sensitization	status	were	shown	to	be	useful	and	clini‐
cally	accessible	biomarkers	to	guide	response	to	treatment.66
4  | UNANSWERED QUESTIONS FOR 
OMALIZUMAB THER APY IN THE PEDIATRIC 
A STHMA POPUL ATION
Considerations	 for	 omalizumab	 therapy	 in	 pediatric	 patients	 are	
listed	 in	 Table	 3.	 Viruses,	 particularly	 rhinoviruses,	 are	 associated	
with	the	majority	of	asthma	exacerbations	in	children,	which	occur	
frequently	 during	 the	 autumnal	 season	 upon	 the	 recommence‐
ment	 of	 the	 school	 year.67	 Interestingly,	 reduced	 susceptibility	 to	
virus‐induced	 asthma	 exacerbations	 with	 omalizumab	 in	 children	
(6–17	years)	has	been	demonstrated.67,68	Mechanistically,	this	exac‐
erbation	reduction	 is	believed	to	be	 linked	to	enhanced	 interferon	
(IFN)‐α	responses.67	A	similar	impact	on	anti‐viral	responses	in	chil‐
dren	 has	 not	 yet	 been	 demonstrated	with	 another	 biologic	 agent,	
but	the	results	of	such	studies	would	be	important	additions	to	our	
scientific	 knowledge	 on	 exacerbation	 prevention	 and	 reduction	 in	
children.	The	true	potential	impact	of	early‐life	IgE	blockage	on	the	
future	development	of	 asthma	 remains	 to	be	 further	 investigated.	
The	results	of	the	PARK	and	EXPECT69	(discussed	later)	studies	may	
add	further	insights.
Pediatric	 asthma	 patients	 often	 suffer	 significant	 multi‐mor‐
bidity,	 including	 allergic	 rhinitis	 and	 food	 allergy.70,71	 Importantly,	
omalizumab	has	been	 shown	 to	be	effective	 in	allergic	 rhinitis	 (by	
significantly	 improving	 total	Rhinitis	Quality	 of	 Life	Questionnaire	
score).72	Furthermore,	 the	efficacy	of	omalizumab	 in	patients	with	
food	 allergy	 is	 encouraging;	 omalizumab	 decreased	 or	 eliminated	
food	allergy	 symptoms	upon	accidental	exposure	 to	 foods	against	
which	they	were	sensitized.73	However,	there	is	still	a	paucity	of	ev‐
idence	 for	 similar	 therapeutic	 action	 in	 affected	 patients	 <6	years	
of	age.	This	suggests	an	unmet	need	to	 investigate	the	efficacy	of	
omalizumab,	 and	 other	 anti‐IgE	 therapies,	 in	 young	 children	 with	
multi‐morbid	asthma.
Patients	with	allergic	multi‐morbidities	are	more	likely	to	be	sen‐
sitized	to	a	multitude	of	allergen	molecules	as	a	consequence	of	the	
so‐called	“molecular	spreading”	process.74	These	patients	are	easily	
identifiable	by	serum	IgE	testing	with	microarray	technology,	are	less	
responsive	to	allergen	immunotherapy,	and	would	probably	benefit	
from	a	more	comprehensive	anti‐IgE	treatment.75	Specific	 trials	of	
the	 impact	of	anti‐IgE	 therapy	 in	extremely	polysensitized	asthma	
patients	are	still	lacking.
Although	 omalizumab	 is	 available	 for	 certain	 asthma	 patients	
aged	6–17	years,	 there	 is	still	 room	to	 improve	accessibility	to	this	
drug.	 The	 omalizumab	 dosing	 table	 is	 an	 important	 consideration,	
whereby	serum	IgE	 levels	and	body	weight	must	be	taken	 into	ac‐
count	when	calculating	drug	dose.	However,	patients	in	whom	pre‐
treatment	 serum	 IgE	 levels	 exceed	 the	 upper	 limits	 of	 the	 dosing	
table	are	deemed	ineligible	for	this	therapy,76	even	though	it	is	not	
uncommon	for	patients	with	severe	disease	to	show	such	excessively	
high	IgE	levels.	This	is	particularly	frustrating	for	families	and	physi‐
cians	 of	 children	 for	whom	 there	 are	 no	 alternative	 anti‐IgE	 ther‐
apies	 currently	 licensed.	 Studies	 assessing	 omalizumab	 in	 patients	
with	total	IgE	>1500	IU/mL,	new	protocols	with	decreasing	doses,	or	
less	frequent	administration	after	omalizumab	initiation	in	controlled	
patients	are	needed.	Moreover,	growth	curves	of	“normal”	total	IgE	
levels	throughout	childhood	have	been	recently	reported77 and may 
help	 in	 revising	 and	 expanding	 the	 criteria	 for	 eligibility	 for	 omal‐
izumab	 treatment.	 Finally,	 the	 fact	 that	 there	 are	 two	parameters	
(serum	IgE	and	body	weight)	involved	in	the	dosing	table	may	be	an	
added	complication	for	some	physicians.
TA B L E  3  Considerations	for	omalizumab	use	in	the	pediatric	
asthma	population
Reduction	of	viral‐induced	exacerbations
Potential	to	treat	multi‐morbidities,	including	allergic	rhinitis	and	
food	allergy
Limitations	of	the	dosing	table
Potential	for	home	administration
Good	safety	profile
PAPADOPOULOS et AL.      |  13
As	 omalizumab	 is	 a	 treatment	 that	 is	 administered	 every	 2	 or	
4	weeks,	 the	 opportunity	 to	 administer	 the	 medication	 at	 home	
would	be	of	great	benefit	for	both	patients	and	busy	parents/guard‐
ians.	 Home	 administration	 is	 currently	 performed	 in	 France	 by	 a	
nurse	or	GP.	However,	 the	convenience	of	home	use	must	be	bal‐
anced	with	the	risk	of	omalizumab‐associated	anaphylaxis,	a	serious,	
albeit	very	rare	occurrence,	affecting	0.1%–0.2%	of	patients	receiv‐
ing	this	biologic	agent.78
Alternative	 biologic	 options	 with	 safe	 and	 flexible	 dosing	
regimens	 are	 welcome.	 As	 new	 biologics	 such	 as	 anti‐IL‐5	 and	
anti‐IL‐4/‐13	therapies	are	emerging,	it	will	become	increasingly	im‐
portant	to	ensure	that	physicians	have	optimal	educational	support	
when	choosing	the	appropriate	biologic	for	the	appropriate	patient	
to	maximize	the	clinical	outcomes	for	the	pediatric	patient.	This	may	
include	the	identification	of	an	easily	accessible	biomarker	to	distin‐
guish	between	inflammatory	phenotypes	in	children.	Further	studies	
of	the	safety	and	efficacy	of	these	biologics	in	younger	patients	will	
certainly	help	to	fill	current	gaps	in	our	knowledge.33
5  | OMALIZUMAB AND PREGNANCY
An	observational	study	assessing	the	safety	of	omalizumab	during	
pregnancy	is	also	currently	underway.	The	EXPECT	omalizumab	preg‐
nancy	 registry	 (https://clinicaltrials.gov/ct2/show/NCT00373061)	
records	the	incidence	of	congenital	anomalies	in	babies	born	to	asth‐
matic	mothers	who	were	exposed	to	≥1	dose	of	omalizumab	8	weeks	
before	conception	or	at	any	time	during	pregnancy.	Interim	analysis	
of	the	EXPECT	study	has	revealed	no	increase	in	the	prevalence	of	
major	anomalies	in	babies	of	asthmatic	mothers	who	were	exposed	
to	 omalizumab	 (via	 the	 feto‐maternal	 barrier)	 compared	 with	 the	
general	 asthma	population.69	Observational	 data	 for	 the	 newborn	
are	 also	 collected	 at	 birth,	 and	 at	 6	 and	 12	months	 post‐delivery	
(and	 up	 to	 18	months	 post‐delivery	 if	 the	 infant	 is	 being	 breast‐
fed).	Therefore,	when	completed,	this	study	is	expected	to	provide	
much‐needed	safety	 information	on	the	use	of	omalizumab	during	
pregnancy,	while	also	facilitating	the	assessment	of	longer‐term	pre‐
ventative	and	safety	outcomes	in	these	children.	Similar	studies	in‐
volving	the	assessment	of	other	biologic	therapies	would	be	highly	
beneficial.
6  | FINAL CONSIDER ATIONS
Asthma	is	a	condition	that	often	begins	in	young	children.	If	asthma	is	
adequately	treated	to	establish	control	early	in	life,	it	is	possible	that	
these	young	patients	will	experience	improved	quality	of	life,	improved	
lung	function,	reduced	morbidity	and	asthma	severity	as	adults,	cou‐
pled	with	potential	cost	savings	for	healthcare	systems.	This	hypoth‐
esis	is	supported	by	the	recent	Finnish	experience,	in	which	improved	
asthma	control	 resulted	 in	 significant	cost	 savings	 through	 reduced	
healthcare	utilization.79	 In	order	 to	achieve	 this	globally,	 the	unmet	
needs	in	the	management	of	asthma	must	be	addressed.
As	asthma	is	one	of	the	most	common	conditions	affecting	chil‐
dren,1	 both	 primary	 care	 providers	 and	 specialists	 play	 important	
roles	 in	 diagnosis	 and	management.29	 Furthermore,	 dissemination	
and	implementation	of	evidence‐based	guidelines	to	ensure	efficient	
and	appropriate	escalation	of	therapy	are	critical.
There	 is	 still	 a	 paucity	 of	 clinical	 evidence	 available,	 or	 being	
generated,	to	support	specific	treatment	(including	biologic)	recom‐
mendations	in	all	children,	especially	those	<6	years	of	age,	as	well	
as	a	lack	of	non‐steroid‐based	treatment	options	indicated	for	or	as‐
sessed	in	this	age	group.	More	adolescents	and	young	children	must	
be	accommodated	in	ongoing	and	future	planned	clinical	trials	of	bio‐
logic	therapies.	Through	studies	like	these,	clinical	data	may	be	used	
to	support	guideline	committees	in	making	informed	recommenda‐
tions	for	all	patients	with	asthma.	Studies	exploring	the	potential	for	
asthma	prevention	or	disease	modification	are	urgently	needed	also.	
The	inclusion	of	tools	to	support	the	prevention	of	long‐term	effects	
of	childhood	asthma	should	be	considered	by	committees	for	future	
asthma	guidelines;	these	could	include	recommendations	for	contin‐
uous	monitoring	of	spirometry	over	time	to	map	lung	function	during	
childhood,	 the	use	of	 the	CASI	 (as	 is	being	employed	 in	 the	PARK	
study),	and	an	increased	emphasis	on	the	use	of	technology	to	mon‐
itor	treatment	adherence.80	Further	biomarker	studies	in	children	to	
build	upon	current	evidence	for	stratified	treatment	approaches	are	
also	encouraged,	to	ensure	timely	and	early	therapeutic	intervention	
to	maximize	clinical	outcomes.
An	increased	focus	on	children	in	the	context	of	asthma	guide‐
lines	would	be	welcome;	current	pediatric	practice	often	 relies	on	
extrapolations	from	adult	 recommendations	due	to	a	 lack	of	avail‐
able	 clinical	 trial	 data	 in	 young	 children	 and	 adolescents.	Uniform	
and	conclusive	definitions	of	pediatric	asthma	and	pediatric	asthma	
control	are	needed.	Studies	assessing	safety	and	efficacy	of	biolog‐
ics	with	outcomes	that	are	relevant	to	pediatric	asthma	patients	are	
warranted,	including	the	impact	on	the	quality	of	life	of	the	child	and	
caregiver	as	composite	end‐points.	The	outcomes	of	these	studies	
may	then	be	used	as	evidence	to	support	specific	treatment	recom‐
mendations	in	clinical	practice	guidelines,	which	are	directly	relevant	
for	younger	patients,	and	which	would	resonate	with	parents/guard‐
ians	and	healthcare	practitioners.	Findings	may	also	facilitate	 label	
modifications	of	certain	therapies	to	include	use	in	younger	patients.	
Emerging	 therapies	 with	 novel	 targets	 and	 mechanisms	 of	 action	
also	need	to	be	studied	in	the	pediatric	patient	population	to	ensure	
that	therapy	can	be	optimized	for	individual	patients,	regardless	of	
age,	disease	severity,	or	endotype.
Since	the	approval	of	omalizumab	over	ten	years	ago,	there	have	
been	many	studies	demonstrating	its	benefits	in	children	≥6	years	of	
age;	however,	the	biologic	therapeutic	options	available	to	younger	
asthma	 patients	 are	 limited.	With	 more	 evidence	 of	 efficacy	 and	
safety	 in	 this	 vulnerable	 patient	 population,	 there	 is	 considerable	
potential	 for	 early	 intervention	 with	 omalizumab	 in	 these	 very	
young	 patients	 to	 improve	 clinical	 outcomes	 and	 possibly	 reduce	
disease	progression	and/or	severity.	Studies	that	demonstrate	effi‐
cacy	of	omalizumab	in	younger	patients	are	needed	and	are	planned.	
Evidence	of	disease‐modifying	and/or	disease	prevention	potential	
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of	 omalizumab	 in	 pediatric	 asthma	 is	 needed	 to	 support	 the	 use	
of	omalizumab	 in	younger	patients	with	uncontrolled	disease	who	
may	significantly	benefit	from	such	therapy,	but	who	are	currently	
excluded.	This	unmet	need	may	be	addressed	in	part	by	the	PARK	
study.	Earlier	intervention	with	omalizumab	in	appropriate	patients	
may	 reduce	 or	 prevent	 the	 use	 of	 corticosteroids,	 inhaled	 or	 sys‐
temic,	to	maintain	control	in	a	patient	population	that	is	particularly	
vulnerable	to	adverse	events	associated	with	ICS	or	OCS.
Optimal	management	of	pediatric	asthma	also	involves	the	criti‐
cal	step	of	specialist	referral	of	uncontrolled	or	difficult‐to‐treat	pa‐
tients	 in	countries	where	asthma	 treatment	 is	 largely	delivered	by	
the	GP/PCP.14	An	increased	understanding	of	the	potential	benefits	
of	anti‐IgE	therapy	in	multi‐morbid	asthmatic	children	is	also	needed	
to	 ensure	 that	 patients	 are	 optimally	 treated,	 with	 specific	 label	
changes	implemented	where	appropriate.
Finally,	 it	 is	 widely	 acknowledged	 that	 there	 are	 many	 unmet	
needs	which	remain	to	be	addressed	in	the	management	of	pediat‐
ric	asthma	patients.	Prevention	measures,	biomarker	analyses,	and	
age‐specific	treatment	recommendations	are	just	some	of	the	ways	
in	which	the	management	of	this	condition	may	be	driven	forward	in	
order	to	benefit	as	many	patients	and	families	as	possible.
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